The DEA on Oct. 6 announced the second temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications. The first temporary rule issued May 10, 2023, extended certain exceptions granted to existing DEA regulations in March 2020 as a result of the COVID-19 Public Health Emergency. Through this rule, effective Nov. 11, DEA and HHS are further extending such exceptions through Dec. 31, 2024.
More information is available at DEA.gov.
